The Latest Breaking News from Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.

Benzinga · Jul 14, 2025

Crude Oil Down Over 2%; Delta Air Lines Posts Upbeat Earnings

U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining more than 200 points on Thursday.

Benzinga · Jul 10, 2025

US Stocks Mixed; Initial Jobless Claims Fall

U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 100 points on Thursday.

Benzinga · Jul 10, 2025

What 6 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical

Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter:

Benzinga · Jul 1, 2022

Expert Ratings for Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings within the last quarter:

Benzinga · May 24, 2022

Citigroup Maintains Buy Rating for Ultragenyx Pharmaceutical: Here's What You Need To Know

Citigroup has decided to maintain its Buy rating of Ultragenyx Pharmaceutical (NASDAQ:RARE) and lower its price target from $150.00 to $146.00. Shares of Ultragenyx Pharmaceutical are trading up 2.9% over the last 24 hours, at $53.30 per share.

Benzinga · May 10, 2022

What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical

Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter:

Benzinga · May 6, 2022

Ultragenyx Pharmaceutical's Earnings Outlook

Ultragenyx Pharmaceutical (NASDAQ:RARE) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Ultragenyx Pharmaceutical will report an earnings per share (EPS) of $-1.76.

Benzinga · May 4, 2022

What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical

Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings:

Benzinga · Mar 16, 2022

Where Ultragenyx Pharmaceutical Stands With Analysts

Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings within the last quarter:

Benzinga · Mar 16, 2022